Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
Stereotaxis Q1 Earnings Call Highlights
10:07pm, Friday, 15'th May 2026
Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products a
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
09:10pm, Tuesday, 12'th May 2026
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
06:40pm, Tuesday, 12'th May 2026
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
04:06pm, Tuesday, 12'th May 2026
Proprietary robotically-navigated MAGiC catheter received U. S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operati
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
01:06pm, Thursday, 23'rd Apr 2026
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
Stereotaxis Announces First MAGiC Procedures in the United States
07:58am, Wednesday, 22'nd Apr 2026
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pat
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
09:01am, Tuesday, 21'st Apr 2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
10:37am, Friday, 17'th Apr 2026
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
Stereotaxis, Inc. (STXS) M&A Call Transcript
02:51pm, Wednesday, 15'th Apr 2026
Stereotaxis, Inc. (STXS) M&A Call Transcript
Stereotaxis Announces Definitive Agreement to Acquire Robocath
07:00am, Wednesday, 15'th Apr 2026
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today annou
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
03:31pm, Tuesday, 07'th Apr 2026
STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
08:06am, Monday, 06'th Apr 2026
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has r
Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks
08:15am, Friday, 13'th Mar 2026
Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
08:17pm, Monday, 09'th Mar 2026
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Monday, 09'th Mar 2026
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
